CryoLife (CRY) Tops Q3 EPS by 3c, Updates FY14 Guidance
Tweet
Share
E-mailGet Alerts CRY Hot Sheet
Join SI Premium – FREE
CryoLife (NYSE: CRY) reported Q3 EPS of $0.08, $0.03 better than the analyst estimate of $0.05. Revenue for the quarter came in at $37.1 million versus the consensus estimate of $37.7 million.
CryoLife sees FY2014 EPS of $0.22-$0.24 vs the consensus of $0.20.
The Company's 2014 financial guidance has been revised and is summarized below.
2014 Financial Guidance Summary | ||
Previous | Current | |
Total revenues | $144 million - $146 million 2% - 4% growth | Same |
Product revenues | Mid to high single-digit % growth | Same |
Tissue processing revenues | Flat | Slight decrease |
R&D expenses | $11.0 million - $12.0 million | $9.0 million - $10.0 million |
Earnings per share | $0.17 - $0.20, including litigation | $0.22 - $0.24, including litigation |
Income tax rate | Approximately 30% | Approximately 25% |
For earnings history and earnings-related data on CryoLife (CRY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- Star Equity Holdings (STRR) Misses Q2 EPS by 8c
- Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
